

**Table 4. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting IFN- $\gamma$**

Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications
IFN- $\gamma$	<b>Emapalumab</b> Anti-IFN- $\gamma$ antibody	•Primary Hemophagocytic Lymphohistiocytosis (HLH)	<b>NCT04324021</b> Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. <b>Interventional Phase 2/3</b>	In patients affected by Adenosine Deaminase Deficiency- Severe Combined Immunodeficiency (ADA-SCID), emapalumab reduced the size of brain lesions caused by CNS Tuberculosis infection (Tucci et al., 2020).